Chen Yu, M.D., M.B.A.
Managing Partner

Chen Yu, M.D., M.B.A. is a Managing Partner based in Palo Alto who joined Vivo in 2004. At Vivo, Dr. Yu invests in both private and public pharmaceutical and medical device companies in the US and China. Dr. Yu has extensive operating experience with leadership roles at both private and public companies, including Sagent Pharmaceuticals (SGNT), China KangHui (KH), and aQuantive (AQNT). Notably, Dr. Yu has played a leading industry role in facilitating cross border deals between emerging market and US healthcare companies. As Chief Business Officer at China KangHui (KH), a leading China based orthopedic company, he helped take the company public on the New York Stock Exchange in 2010 and ultimately led negotiations during the sale to Medtronic for $816 MM in 2012. Most recently, Dr. Yu served as Chief Operating Officer at Sagent Pharmaceuticals (SGNT), which partners with leading companies across Asia and Europe. Dr. Yu currently serves or has served on the boards of several life science companies in both the US and China, including Sentre Heart (US), Rempex (Acquired by MDCO), Nora Therapeutics (US), Jian Rui Bao (China), GMT Medical (China), and Synaptic Medical (China). Other representative investments include Trauson (acquired by Stryker for $764 MM), Durata (DRTX), Achillion (ACHN), Cubist (CBST), and Ocera (OCRX).

Dr. Yu is also active in the community and currently serves on the California Leadership Council for the Nature Conservancy, an environmental non-profit with global reach. He was also previously a member of the Stanford Medical School Alumni Board of Governors. Dr. Yu received his M.D. and M.B.A. from Stanford University and graduated magna cum laude with a B.A. in Biology from Harvard University.